Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07205679

Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate

Heart Failure (HF) and Atrial Fibrillation (AF) are two conditions that commonly occur together. Clinical guidelines consider a resting heart rate of 100-110 beats per minute (bpm) acceptable for patients with HF and AF while 72 bpm is considered the average in healthy populations. A higher resting heart rate indicates that the heart is working harder to meet bodily demands, and though it may be considered safe for patients with HF and AF to have a heart rate of 110 bpm, the investigators believe it is having a significant negative impact on patient quality of life and their ability to exercise. The current study will test exercise ability using a treadmill test before and after either a cardioversion, where the patient's heartbeat is reset using electric shocks, or a pace and ablate method, where the patient receives a pacemaker to regulate their heart rhythm and an ablation (intentional damaging) of the node that coordinates the beats within the heart. This will allow investigators to compare how the heart responds to exercise when the patient is on rate-control and anticoagulation medication therapy (before cardioversion or pace and ablate) and after the procedures. During exercise, the investigators will do a blood test that lets investigators know how efficiently the heart is working and record any symptoms experienced. The investigators will also collect information about the patient's quality of life. Using this information, the investigators hope to better understand whether the current standard of a resting heart rate of 100-110 bpm is ideal for patient quality of life.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18
  • Persistent or Permanent Atrial Fibrillation
  • HF - NYHA class II-IVA despite guideline-direct medical therapy
  • Rate controlled
  • Able to perform stress test
  • Scheduled for clinical P&A OR cardioversion

Exclusion criteria

  • Creatinine >180 μmol/L or eGFR <30 mL/min/1.73 m2
  • Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis
  • Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment
  • Right ventricular systolic pressure >50mmHg
  • Existing pacemaker
  • In sinus rhythm
  • Predictable vasovagal syncope to pain and sight of blood

Treatment and study plan

Primary outcomes

  1. Exercise duration

    Time frame: 1 month

  2. Peak oxygen update

    Time frame: 1 month

    Peak oxygen uptake achieved during a symptom-limited incremental exercise test to task failure.

  3. B-type Natriuretic Peptide (BNP) Test

    Time frame: 1 month

Secondary outcomes

  1. Change in maximal HR during exercise

    Time frame: 1 month

  2. EuroQol (EQ-5D-5L)

    Time frame: 1 month

    Participants indicate abilities with respect to five dimensions of health. Higher scores indicate greater impairment.

  3. Rate of Perceived exertion change during exercise

    Time frame: 1 month

  4. V̇O2peak change

    Time frame: 1 month

  5. Change in lactate threshold

    Time frame: 1 month

  6. Kansas City Cardiomyopathy Questionnaire

    Time frame: 1 month

    Change in Kansas HF score from baseline. KCCQ is a 23-item self-administered questionnaire that measures the participant's perception of their health status, including their HF symptoms, impact on physical and social function and how their HF impacts the quality of life (QoL). KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), QoL (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status.

Study contacts

Contact information is provided by the study sponsor or research team.

Abbie Pardo, MSc

CONTACT

[email protected]

5196612111 ext. 86459

Sponsors and collaborators

Lead sponsor

Habib Khan

Other

Registry information

Acronym: CPEX-CPA

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 3, 2025
Registry last updated
Oct 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.